Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:10 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524804 | NSE: AUROPHARMA

Aurobindo Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,186.93Overvalued by 11.56%vs CMP ₹1,342.00

P/E (22.1) × ROE (11.1%) × BV (₹603.00) × DY (0.30%)

₹891.76Overvalued by 33.55%vs CMP ₹1,342.00
MoS: -50.5% (Negative)Confidence: 53/100 (Moderate)Models: 3 Fair, 6 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,256.2722%Fair (-6.4%)
Graham NumberEarnings₹902.5516%Over (-32.7%)
Earnings PowerEarnings₹298.3311%Over (-77.8%)
DCFCash Flow₹707.7113%Over (-47.3%)
Net Asset ValueAssets₹603.287%Over (-55%)
EV/EBITDAEnterprise₹1,277.569%Fair (-4.8%)
Earnings YieldEarnings₹600.407%Over (-55.3%)
ROCE CapitalReturns₹1,234.649%Fair (-8%)
Revenue MultipleRevenue₹546.175%Over (-59.3%)
Consensus (9 models)₹891.76100%Overvalued
Key Drivers: Wide model spread (₹298–₹1,278) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 5.8%

*Investments are subject to market risks

Investment Snapshot

66
Aurobindo Pharma Ltd scores 66/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health76/100 · Strong
ROCE 14.2% GoodROE 11.1% AverageD/E 0.22 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.38% (6mo) SellingDII holding up 1.43% MF buyingPromoter holding at 51.8% Stable
Earnings Quality75/100 · Strong
OPM expanding (17% → 21%) ImprovingWorking capital: 49 days (improving) Efficient
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +7% YoY GrowingProfit (4Q): 0% YoY Declining
Industry Rank65/100 · Strong
P/E 22.1 vs industry 53.8 Cheaper than peersROCE 14.2% vs industry 16.4% Average3Y sales CAGR: 11% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:10 am

Market Cap 77,949 Cr.
Current Price 1,342
Intrinsic Value₹891.76
High / Low 1,360/994
Stock P/E22.1
Book Value 603
Dividend Yield0.30 %
ROCE14.2 %
ROE11.1 %
Face Value 1.00
PEG Ratio3.78

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Aurobindo Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Aurobindo Pharma Ltd 77,949 Cr. 1,342 1,360/99422.1 6030.30 %14.2 %11.1 % 1.00
Mankind Pharma Ltd 82,619 Cr. 2,001 2,727/1,91046.8 3760.05 %15.0 %13.9 % 1.00
Alkem Laboratories Ltd 62,655 Cr. 5,244 5,934/4,61226.1 1,1160.86 %20.4 %19.4 % 2.00
Cipla Ltd 96,603 Cr. 1,196 1,673/1,19420.3 4081.09 %22.7 %17.8 % 2.00
Glenmark Life Sciences Ltd 59,293 Cr. 2,101 2,298/1,33621.9 3400.12 %19.4 %15.8 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Aurobindo Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 6,4076,4736,8517,2197,3527,5807,5677,7967,9798,3827,8688,2868,646
Expenses 5,4535,4775,7025,8465,7535,9205,9496,2306,4016,6226,2656,6086,873
Operating Profit 9549961,1491,3731,5991,6601,6181,5661,5781,7601,6031,6781,773
OPM % 15%15%17%19%22%22%21%20%20%21%20%20%21%
Other Income 931354718816314221136159135107122123
Interest 455657687689111113118115989593
Depreciation 321346327418423354404382419444406429465
Profit before tax 6807308121,0761,2621,2301,3241,2071,2001,3351,2071,2761,339
Tax % 28%31%30%30%26%26%31%32%30%32%32%34%32%
Net Profit 491506570752940907918817846903824848910
EPS in Rs 8.388.649.7412.9215.9815.5115.6914.0714.5615.5614.2014.6115.67

Last Updated: March 3, 2026, 12:04 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:30 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 8,08912,10313,77214,91016,46319,56423,09924,77523,45524,85529,00231,72433,182
Expenses 5,9519,52410,57911,46912,69115,61218,24919,49719,06021,14823,17625,17326,368
Operating Profit 2,1372,5793,1933,4413,7723,9524,8495,2784,3963,7075,8266,5516,814
OPM % 26%21%23%23%23%20%21%21%19%15%20%21%21%
Other Income 1881200115105701663,195152291366622487
Interest 31016025767782633057449140290457401
Depreciation 3133333924285586689671,0551,1271,2451,5221,6491,744
Profit before tax 1,5332,1682,7443,0613,2413,0913,7437,3443,3732,6124,3805,0665,156
Tax % 24%28%26%25%25%24%24%27%22%26%28%31%
Net Profit 1,1691,5712,0242,3012,4232,3642,8445,3342,6471,9283,1693,4843,485
EPS in Rs 20.1226.9834.6139.2941.3640.3648.5691.0545.2032.9054.1560.0260.04
Dividend Payout % 7%8%7%6%6%6%6%4%20%23%8%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)34.39%28.84%13.69%5.30%-2.43%20.30%87.55%-50.37%-27.16%64.37%9.94%
Change in YoY Net Profit Growth (%)0.00%-5.55%-15.15%-8.38%-7.74%22.74%67.25%-137.93%23.21%91.53%-54.43%

Aurobindo Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:10%
5 Years:7%
3 Years:11%
TTM:8%
Compounded Profit Growth
10 Years:8%
5 Years:4%
3 Years:8%
TTM:-5%
Stock Price CAGR
10 Years:4%
5 Years:5%
3 Years:24%
1 Year:-32%
Return on Equity
10 Years:15%
5 Years:12%
3 Years:10%
Last Year:11%

Last Updated: September 5, 2025, 2:31 pm

Balance Sheet

Last Updated: December 10, 2025, 3:52 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 29295959595959595959595858
Reserves 3,7215,1277,2299,31311,62213,83216,76621,87124,51726,78129,78432,59534,983
Borrowings 3,7694,4515,0413,3644,7706,9675,8265,3392,8515,2866,6488,2637,794
Other Liabilities 1,9703,3033,5683,4644,4925,4146,1136,1476,2117,3798,2278,5669,710
Total Liabilities 9,49012,91015,89616,20020,94226,27128,76533,41633,63839,50544,71749,48252,546
Fixed Assets 2,7223,7064,1804,8346,5218,4759,3969,37410,53211,02414,49314,79417,741
CWIP 3104208481,4581,5831,6681,9863,0623,7475,3903,8694,9003,039
Investments 2020123246312360555591997543372252268
Other Assets 6,4398,76510,7459,66212,52715,76816,82720,39018,36222,54925,98329,53631,498
Total Assets 9,49012,91015,89616,20020,94226,27128,76533,41633,63839,50544,71749,48252,546

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 6461,2371,4203,2791,9551,6514,3813,3295,0162,3872,4353,925
Cash from Investing Activity + -819-1,017-1,446-1,787-1,927-2,904-1,563597-3,211-3,971-4,242-1,866
Cash from Financing Activity + 11893365-1,9158641,919-1,947-1,365-2,9691,814800120
Net Cash Flow -55313340-4248926668712,561-1,164230-1,0072,178
Free Cash Flow 272491-1461,5947141142,9691,5032,693-323-1,0671,408
CFO/OP 46%67%67%118%70%61%106%87%143%84%72%86%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-1.00-2.00-2.000.00-1.00-3.00-1.000.002.00-2.00-1.00-2.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 119107122686864685262666166
Inventory Days 240239240246317304289333272275284295
Days Payable 1371361461221281079710397125129117
Cash Conversion Cycle 222210217191257260260282237216216244
Working Capital Days 565044515025355284556649
ROCE %27%27%27%25%23%18%19%18%13%9%14%14%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 51.84%51.84%51.84%51.84%51.84%51.80%51.82%51.82%51.82%51.82%51.82%51.82%
FIIs 23.03%24.12%22.45%20.72%18.01%16.73%16.59%16.29%15.33%14.38%14.21%13.95%
DIIs 15.09%15.73%18.29%20.60%23.28%24.77%25.14%25.21%26.23%26.93%27.60%27.66%
Government 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.03%
Public 10.06%8.31%7.43%6.85%6.87%6.69%6.45%6.67%6.61%6.88%6.37%6.55%
No. of Shareholders 3,43,6172,93,2142,59,6382,41,9442,44,5752,38,6222,48,4882,57,9622,69,3232,72,2082,47,6622,36,859

Shareholding Pattern Chart

No. of Shareholders

Aurobindo Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Mid Cap Fund 13,344,745 1.73 1628.59N/AN/AN/A
Quant ELSS Tax Saver Fund 6,710,355 6.78 818.935,174,2772026-02-23 00:53:0429.69%
Quant Mid Cap Fund 5,969,000 9.92 728.46N/AN/AN/A
SBI Large & Midcap Fund 5,400,000 1.7 659.026,500,0002026-03-23 01:28:44-16.92%
Quant Multi Cap Fund 4,294,483 7.21 524.1N/AN/AN/A
ICICI Prudential India Opportunities Fund 3,775,289 1.29 460.744,403,9872026-03-24 00:22:07-14.28%
ICICI Prudential Value Fund 3,230,588 0.65 394.26N/AN/AN/A
Quant Flexi Cap Fund 3,030,611 5.82 369.86N/AN/AN/A
HDFC Balanced Advantage Fund 2,722,312 0.31 332.23N/AN/AN/A
HDFC Large and Mid Cap Fund 2,177,529 0.93 265.75N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 59.8154.1632.9045.1991.05
Diluted EPS (Rs.) 59.8154.1632.9045.1991.05
Cash EPS (Rs.) 88.9280.3554.3464.94109.99
Book Value[Excl.RevalReserv]/Share (Rs.) 562.21509.49458.30419.42374.28
Book Value[Incl.RevalReserv]/Share (Rs.) 562.21509.49458.30419.42374.28
Revenue From Operations / Share (Rs.) 546.21495.00424.23400.33422.85
PBDIT / Share (Rs.) 124.05109.2468.4380.3497.53
PBIT / Share (Rs.) 95.6583.2747.1961.1179.52
PBT / Share (Rs.) 87.7875.0544.7958.10126.28
Net Profit / Share (Rs.) 60.5254.3833.1045.7191.98
NP After MI And SOA / Share (Rs.) 60.0254.1632.9045.2091.05
PBDIT Margin (%) 22.7122.0616.1320.0623.06
PBIT Margin (%) 17.5116.8211.1215.2618.80
PBT Margin (%) 16.0615.1610.5514.5129.86
Net Profit Margin (%) 11.0810.987.8011.4121.75
NP After MI And SOA Margin (%) 10.9810.947.7511.2921.53
Return on Networth / Equity (%) 10.6710.637.1810.7724.32
Return on Capital Employeed (%) 15.8214.849.7313.8920.09
Return On Assets (%) 7.007.034.837.8015.75
Long Term Debt / Equity (X) 0.040.070.020.010.01
Total Debt / Equity (X) 0.240.210.180.090.22
Asset Turnover Ratio (%) 0.660.680.670.690.78
Current Ratio (X) 1.851.981.872.221.86
Quick Ratio (X) 1.131.181.131.301.01
Inventory Turnover Ratio (X) 3.121.181.200.880.99
Dividend Payout Ratio (NP) (%) 0.000.0022.799.954.39
Dividend Payout Ratio (CP) (%) 0.000.0013.856.983.66
Earning Retention Ratio (%) 0.000.0077.2190.0595.61
Cash Earning Retention Ratio (%) 0.000.0086.1593.0296.34
Interest Coverage Ratio (X) 15.7622.0928.5496.7776.71
Interest Coverage Ratio (Post Tax) (X) 8.6912.6614.8058.7035.56
Enterprise Value (Cr.) 67055.1863875.8029138.9437374.6151145.96
EV / Net Operating Revenue (X) 2.112.201.171.592.06
EV / EBITDA (X) 9.319.987.277.948.95
MarketCap / Net Operating Revenue (X) 2.122.201.221.672.08
Retention Ratios (%) 0.000.0077.2090.0495.60
Price / BV (X) 2.062.141.131.592.36
Price / Net Operating Revenue (X) 2.122.201.221.672.08
EarningsYield 0.050.040.060.060.10

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 10933.30 Cr. and Equity Capital is Rs. 58.08 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No.2, Maitri Vihar, Hyderabad Telangana 500038Contact not found
Management
NamePosition Held
Mr. M Ramasubramanian KumarNon Exe.Chairman&Ind.Director
Mr. K Nithyananda ReddyVice Chairman & Mng.Director
Mr. M Madan Mohan ReddyWhole Time Director
Mr. P V Ramprasad ReddyNon Executive Director
Dr. Satakarni MakkapatiNon Executive Director
Mr. P Sarath Chandra ReddyNon Executive Director
Mr. Girish P VanvariIndependent Director
Mr. Santanu MukherjeeIndependent Director
Dr. Deepali Pant JoshiIndependent Director

FAQ

What is the intrinsic value of Aurobindo Pharma Ltd and is it undervalued?

As of 18 April 2026, Aurobindo Pharma Ltd's intrinsic value is ₹891.76, which is 33.55% lower than the current market price of ₹1,342.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (11.1 %), book value (₹603), dividend yield (0.30 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd is trading at ₹1,342.00 as of 18 April 2026, with a FY2026-2027 high of ₹1,360 and low of ₹994. The stock is currently near its 52-week high. Market cap stands at ₹77,949 Cr..

How does Aurobindo Pharma Ltd's P/E ratio compare to its industry?

Aurobindo Pharma Ltd has a P/E ratio of 22.1, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Aurobindo Pharma Ltd financially healthy?

Key indicators for Aurobindo Pharma Ltd: ROCE of 14.2 % is moderate. Dividend yield is 0.30 %.

Is Aurobindo Pharma Ltd profitable and how is the profit trend?

Aurobindo Pharma Ltd reported a net profit of ₹3,484 Cr in Mar 2025 on revenue of ₹31,724 Cr. Compared to ₹2,647 Cr in Mar 2022, the net profit shows an improving trend.

Does Aurobindo Pharma Ltd pay dividends?

Aurobindo Pharma Ltd has a dividend yield of 0.30 % at the current price of ₹1,342.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aurobindo Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports